Textron reported its fourth-quarter 2024 earnings with an adjusted EPS of $1.34, exceeding estimates of $1.28. However, revenue came in at $3.61 billion, below the expected $3.73 billion. Looking ahead, Textron anticipates an adjusted EPS between $6.00 and $6.20 for 2025, lower than the estimate of $6.39. Abbott Laboratories also released its fourth-quarter 2024 earnings, reporting an adjusted EPS of $1.34, which met expectations, while revenue was $10.97 billion, slightly missing the forecast of $11.01 billion. Abbott projects an adjusted EPS for 2025 between $5.05 and $5.25, with estimates at $5.16. The company also expects Q1 adjusted EPS to be between $1.05 and $1.09, below the estimate of $1.11. Abbott's net income for the quarter was $9.23 billion, influenced by an extraordinary tax impact, and it saw strong sales growth in its device segment, particularly the FreeStyle Libre, which grew by 22.75%. Amphenol reported an adjusted EPS of $0.55, surpassing estimates of $0.51, with revenues of $4.32 billion exceeding expectations of $4.08 billion. The company projects Q1 sales between $4.00 billion and $4.10 billion, with adjusted EPS expectations between $0.49 and $0.51.